Real-World Data from Italy: Luspatercept Shows Promise in Transfusion-Dependent Beta-Thalassemia
Mostafa Faisal, associate professor of Adult Hematology and BMT, recently shared a post on use of Luspatercept on X:
”Luspatercept for Transfusion-Dependent Beta-Thalassemia: Real-World Experience in a Large Cohort of Patients From Italy – The American Journal of Hematology.”
Read the full article here.
Following the approval of the drug in the U.S. and Europe—based on the findings of the randomized, placebo-controlled phase III BELIEVE trial—there remained a need to generate robust real-world evidence on its effectiveness, safety, and tolerability in routine clinical settings.
To address this, the impact of luspatercept treatment in a cohort of 231 individuals with TDT was assessed.
Published in the American Journal of Hematology, this new study presents one of the largest real-world cohorts examining the use of the drug in patients with transfusion-dependent beta-thalassemia (TDT) across Italy.
To learn more on new scientific advances in hematology, read Hemostasis Today.
-
Aug 26, 2026, 10:09Gemma Figtree: How Well Do We Predict Heart Attack Risk in Women?
-
Aug 26, 2026, 10:06Understanding and Managing Fatigue in ITP – ITP Support Association
-
Aug 26, 2026, 10:04Abdul Muqtadir Abbasi: When a High INR Hides a Thrombotic Cancer
-
Aug 26, 2026, 09:42Mohammed Alo: What’s Wrong With the New Blood Pressure Guidelines?
-
Aug 26, 2026, 09:01Mary Cushman: The Role of IL-6 in Cardiovascular Disease
-
Aug 26, 2026, 07:49Linda Koch: Understanding Ageing Through Biological Transitions
-
Aug 26, 2026, 05:38Elias Lee։ Beyond MCA Stenosis – Recognizing Moyamoya
-
Aug 26, 2026, 03:46Hugo Ribeiro: Which NSAIDs Are Safest for Older Adults?
-
Aug 25, 2026, 19:45Cara T. Hoepner: Omega-3 is Not an Exposure